Handelsbanken Fonder’s Vertex Pharmaceuticals VRTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $108M | Sell |
218,292
-2,555
| -1% | -$1.13M | 0.31% | 57 |
|
|
2026
Q1 | $98.6M | Buy |
220,847
+4,516
| +2% | +$2.11M | 0.33% | 53 |
|
|
2025
Q4 | $98.1M | Buy |
216,331
+1,571
| +0.7% | +$677K | 0.3% | 59 |
|
|
2025
Q3 | $84.1M | Buy |
214,760
+467
| +0.2% | +$195K | 0.27% | 71 |
|
|
2025
Q2 | $95.4M | Buy |
214,293
+6,648
| +3% | +$3.06M | 0.34% | 62 |
|
|
2025
Q1 | $101M | Sell |
207,645
-88,391
| -30% | -$41.2M | 0.42% | 45 |
|
|
2024
Q4 | $119M | Sell |
296,036
-115,479
| -28% | -$53.5M | 0.46% | 37 |
|
|
2024
Q3 | $191M | Sell |
411,515
-4,866
| -1% | -$2.34M | 0.76% | 19 |
|
|
2024
Q2 | $195M | Buy |
416,381
+145,696
| +54% | +$63.2M | 0.85% | 16 |
|
|
2024
Q1 | $113M | Buy |
270,685
+10,412
| +4% | +$4.4M | 0.49% | 32 |
|
|
2023
Q4 | $106M | Sell |
260,273
-21,880
| -8% | -$8.08M | 0.51% | 32 |
|
|
2023
Q3 | $98.1M | Sell |
282,153
-3,780
| -1% | -$1.32M | 0.55% | 32 |
|
|
2023
Q2 | $101M | Sell |
285,933
-49,918
| -15% | -$16.8M | 0.54% | 32 |
|
|
2023
Q1 | $106M | Buy |
335,851
+5,090
| +2% | +$1.53M | 0.61% | 29 |
|
|
2022
Q4 | $95.5M | Sell |
330,761
-26,056
| -7% | -$7.94M | 0.6% | 31 |
|
|
2022
Q3 | $103M | Buy |
356,817
+6,361
| +2% | +$1.83M | 0.69% | 24 |
|
|
2022
Q2 | $98.8M | Buy |
350,456
+142,575
| +69% | +$38.2M | 0.64% | 25 |
|
|
2022
Q1 | $54.3M | Buy |
207,881
+13,837
| +7% | +$3.28M | 0.3% | 70 |
|
|
2021
Q4 | $42.6M | Buy |
194,044
+121,656
| +168% | +$23.7M | 0.21% | 110 |
|
|
2021
Q3 | $13.1M | Sell |
72,388
-39,633
| -35% | -$7.74M | 0.07% | 273 |
|
|
2021
Q2 | $22.6M | Sell |
112,021
-94,556
| -46% | -$19.8M | 0.12% | 184 |
|
|
2021
Q1 | $44.4M | Buy |
206,577
+3,571
| +2% | +$784K | 0.25% | 89 |
|
|
2020
Q4 | $48M | Buy |
203,006
+25,944
| +15% | +$5.95M | 0.29% | 87 |
|
|
2020
Q3 | $48.2M | Sell |
177,062
-6,020
| -3% | -$1.66M | 0.35% | 65 |
|
|
2020
Q2 | $53.2M | Buy |
183,082
+55,374
| +43% | +$15M | 0.45% | 49 |
|
|
2020
Q1 | $30.4M | Sell |
127,708
-10,000
| -7% | -$2.29M | 0.65% | 46 |
|
|
2019
Q4 | $30.2M | Buy |
137,708
+21,708
| +19% | +$4.39M | 0.52% | 63 |
|
|
2019
Q3 | $19.7M | Buy |
116,000
+15,000
| +15% | +$2.65M | 0.4% | 74 |
|
|
2019
Q2 | $18.5M | Buy |
101,000
+27,000
| +36% | +$4.72M | 0.34% | 81 |
|
|
2019
Q1 | $13.6M | Sell |
74,000
-15,000
| -17% | -$2.77M | 0.26% | 95 |
|
|
2018
Q4 | $14.7M | Buy |
89,000
+8,000
| +10% | +$1.39M | 0.3% | 91 |
|
|
2018
Q3 | $15.6M | Buy |
81,000
+24,000
| +42% | +$4.27M | 0.29% | 97 |
|
|
2018
Q2 | $9.69M | Buy |
57,000
+15,000
| +36% | +$2.33M | 0.19% | 123 |
|
|
2018
Q1 | $6.84M | Buy |
42,000
+8,500
| +25% | +$1.39M | 0.13% | 134 |
|
|
2017
Q4 | $5.02M | Buy |
33,500
+14,500
| +76% | +$2.15M | 0.11% | 135 |
|
|
2017
Q3 | $2.89M | Buy |
+19,000
| New | +$2.86M | 0.07% | 152 |
|
|
2016
Q1 | – | Sell |
-24,618
| Closed | -$3.1M | – | 580 |
|
|
2015
Q4 | $3.1M | Buy |
+24,618
| New | +$2.97M | 0.06% | 263 |
|
Other funds holding VRTX
Handelsbanken Fonder's VRTX Position: Q2 2026 in Review
Handelsbanken Fonder reduced its Vertex Pharmaceuticals (VRTX) stake by 1.2% in Q2 2026, selling an estimated $1.13M and leaving 218,292 shares worth $108M. The position accounts for 0.31% of the portfolio, ranked #57.
Handelsbanken Fonder first reported a position in VRTX in Q4 2015 and has held it in 37 quarters since. The position peaked at $195M in Q2 2024. 784 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.
- Handelsbanken Fonder held 218,292 shares of Vertex Pharmaceuticals worth $108M as of Q2 2026.
- Handelsbanken Fonder sold 2,555 Vertex Pharmaceuticals shares in Q2 2026, an estimated $1.13M.
- Vertex Pharmaceuticals made up 0.31% of Handelsbanken Fonder's portfolio in Q2 2026, its #57 holding.
- Handelsbanken Fonder first reported a position in Vertex Pharmaceuticals in Q4 2015 and has held it in 37 quarters since.
- Handelsbanken Fonder's Vertex Pharmaceuticals position peaked at $195M in Q2 2024.
- 784 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.
Based on Handelsbanken Fonder's 13F filing for Q2 2026, filed 10 Jul 2026.